Key points are not available for this paper at this time.
Colorectal cancer (CRC) exhibits high heterogeneity, affecting variable outcomes and response to therapy. Tumor stroma drives progression and immunosuppression. Although tumor–stroma ratio (TSR) is a validated prognostic marker, TSR remains subjective and poorly reproducible. Artificial intelligence (AI) enables standardized TSR quantification on hematoxylin and eosin (HE) whole-slide images (WSI), supporting clinical integration and personalized therapy. A total of 3411 CRC patients (Cohorts 1–3) were included for survival analysis. HE-stained WSIs were processed using tumor detection and tissue segmentation models to automatically calculate TSR-AI, classified as low, intermediate, or high. Prognostic value for overall survival (OS) and disease-free survival (DFS) was assessed, along with correlations to immune infiltration. Stromal-immune interactions were further validated using spatial transcriptomics data from publicly available CRC samples profiled with Visium HD platform. TSR-AI strongly correlated with reference TSR from CK-stained WSIs (Pearson’s r = 0.93, 95% confidence intervals (CI) 0.90–0.94) and with standardized pathologist assessments (p < 0.05). Patients with TSR-AI-low had significantly prolonged OS compared with TSR-AI-high, with unadjusted hazard ratios of 2.44 (95% CI 1.61–3.70, p < 0.001) in Cohort 1, 3.29 (2.29–4.72, p < 0.001) in Cohort 2, and 2.98 (2.07–4.28, p < 0.001) in Cohort 3; similar trends were observed for DFS. TSR-AI-high was associated with reduced immune cell infiltration. Spatial transcriptomics further revealed stromal-immune interactions, with stroma-high tumors showing elevated cancer-associated fibroblast signatures and enrichment of profibrotic transforming growth factor-β signaling. TSR-AI enables automated, objective, reproducible, and whole-slide quantification of TSR from routine HE-stained WSIs. TSR-AI provides robust prognostic information beyond TNM staging and may inform decisions on postoperative adjuvant therapy. Large-cohort analysis further confirms stroma as a key driver of an immunosuppressive tumor microenvironment in CRC. Not applicable.
Ye et al. (Sat,) studied this question.